Biomedical subjects

Junji Yoshida

Publications and source records attributed to Junji Yoshida.

32 records · Page 2Linked to original sources

PubMed2004

Visceral pleural invasion classification in non-small cell lung cancer: a proposal on the basis of outcome assessment.

OBJECTIVE: The definition of visceral pleural invasion in lung cancer TNM classification of the International Union Against Cancer lacks detail. The purpose of this study was to evaluate the significance of the extent of pleural involvement as a prognostic factor and to propose a refined TNM classification on the basis of visceral pleural invasion. METHODS: We reviewed 1653 consecutive patients with T1, T2, and T3 surgically resected non-small cell lung cancer for their clinicopathologic characteristics and prognoses. Visceral pleural invasion was classified by using the Japan Lung Cancer Society criteria: p0, tumor with no pleural involvement beyond its elastic layer; p1, tumor extension beyond the elastic layer but no exposure on the pleural surface; and p2, tumor exposure on the pleural surface. RESULTS: The 5-year survivals for patients with p1 or p2 tumors of 3 cm or less were identical and significantly worse than those for patients with p0 tumors of the same size. Patients with p1 or p2 tumors of greater than 3 cm and patients with T3 cancers had essentially identical survivals. CONCLUSIONS: Visceral pleural invasion should be defined as tumor extension beyond the elastic layer of the visceral pleura, regardless of its exposure on the pleural surface. A tumor of 3 cm or less with visceral pleural invasion should remain classified as a T2 tumor, as presently occurs in the International Union Against Cancer staging system, and tumors of greater than 3 cm with visceral pleural invasion should be upgraded to T3 status in the International Union Against Cancer TNM classification.

Adult↗

PubMed2004

Late pulmonary metastasis of renal cell carcinoma resected 25 years after nephrectomy.

A 50-year-old male underwent a left nephrectomy for clear cell type renal cell carcinoma (RCC) in February 1978. A right pulmonary metastasis was resected in February 1994. At that time, chest computed tomography revealed the presence of three small nodules in the left lung, but these were followed up as inflammatory lesions. In January 2002, a right pleural metastasis, which showed rapid growth, was detected and it was resected in June of the same year. A gradual growth was observed in the left lung nodules, and the patient underwent wedge resection of the left lung in March 2003, 25 years after nephrectomy. These nodules were diagnosed as metastatic RCC. Currently, the patient is doing well with no signs of recurrence, 8 months after the third metastasectomy.

Adenocarcinoma, Clear Cell↗

PubMed2003

A long-term survivor of complete resection for stage IIB adenocarcinoma of the lung and chemoradiotherapy for postoperative metastasis to the abdominal rectus muscle.

We report long-term survival of very rare metastatic involvement and an unusual course of recurrent stage IIB lung adenocarcinoma. Nine months after surgery for stage IIB primary lung adenocarcinoma, a 64-year-old Japanese man was found to have a nodule in the abdominal rectus muscle, diagnosed histologically as carcinoma metastasizing from the lung. Through combined chemotherapy and subsequent radiotherapy, complete response of the metastatic lesion was achieved without serious adverse effects. Results continue to be favorable more than 7 years and 11 months following sequential chemoradiotherapy and 9 years and 4 months after surgery. Sequential chemoradiotherapy appears to have favorably affected this man's survival despite metachronous metastasis to the abdominal rectus muscle after complete resection for stage IIB primary lung adenocarcinoma.

Adenocarcinoma↗

PubMed2003

The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma.

OBJECTIVE: If non-invasive lung carcinomas are distinguishable on computed tomography (CT), limited surgery can be indicated before operation as a radical procedure. The purpose of this study is to define high resolution CT (HRCT) findings that indicate pathologic T1N0M0 tumor without vessel invasion. PATIENTS AND METHODS: We reviewed HRCT findings and pathological specimens of 98 consecutive patients underwent lobectomy or pneumonectomy with systematic hilar and mediastinal lymph node dissection from January 1996 to October 1999 for 101 pulmonary peripheral adenocarcinomas smaller than 3cm in diameter on HRCT. A total of 101 consecutive surgically resected peripheral adenocarcinomas of the lung measuring 3.0cm or less in the maximum dimension on HRCT were examined both radiologically and histologically. All CT scans ware reviewed by three chest radiologists or pulmonologists. The following parameters were measured on HRCT: the greatest diameter of tumor on found on all CT cuts (Td), the greatest diameter of consolidation found on all CT cuts (Cdmax), and the greatest diameter of consolidation found on a particular CT cut (Cd). Consolidation to tumor size ratio at respective maximum dimensions was calculated as Cdmax/Td, and consolidation to tumor size ratio on the slice image with the maximum tumor dimension was calculated as Cd/Td. One pathologist reviewed all pathological specimens to determine the size of tumor, evidence of vessel invasion, etc. without any information of HRCT, and we compared CT findings with pathological findings. RESULTS: There was a statistically significant difference between tumors with pathologic T1N0M0 adenocarcinoma without vessel invasion (least invasive disease: LID) and tumors with lymph node involvement or vessel invasion (invasive disease: ID) in each parameter. However, only when tumors with Cdmax/Td smaller than 0.5 were selected as LID tumors, could ID tumors be eliminated from the LID group. Five-year survival rate of this population is 95.7%. CONCLUSION: Consolidation to tumor size ratio at respective maximum dimensions was the best predictor of non-invasive peripheral adenocarcinoma.

Adenocarcinoma↗

PubMed2003

Calcification in large cell neuroendocrine carcinoma of the lung.

BACKGROUND: The aim was to investigate the prevalence of intratumoral calcification in large cell neuroendocrine carcinoma (LCNEC) and to review computed tomography (CT) and histological findings. PATIENTS AND METHODS: From August 1992 through March 2000, 35 out of 1183 surgically resected lung cancer patients were histologically diagnosed as having LCNEC at our institute. We reviewed the plain radiographs and CT scans of these 35 LCNEC patients. In LCNEC cases with intratumoral calcification, we examined the size, number, distribution and pattern of intratumoral calcifications visible on the CT scans and the histological features. RESULTS: Three cases (9%) exhibited calcification. The calcifications were recognized by CT scans alone. The CT scans showed punctate or eccentric intratumoral calcifications, which are considered to be a malignant feature, in all three cases. In two cases, the calcifications were histologically confirmed to be located within the necrotic areas of a tumor nest. CONCLUSION: We found three LCNEC cases with intratumoral calcification. The prevalence of LCNEC calcification was similar to that in previous reports on lung cancer. The mechanism of the intratumoral calcification in our LCNEC cases is speculated to be dystrophic calcification.

Aged↗

PubMed2003

Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung.

Squamous cell carcinoma of the lung can be divided into two types according to the location of the primary site: the central type and the peripheral type. The clinicopathologic factors in the peripheral type of lung squamous cell carcinoma have not yet been fully evaluated. A total of 204 surgically resected lung squamous cell carcinomas were reviewed with special reference to their location, histologic characteristics based on tumor growth patterns, and clinicopathologic factors. The central type and the peripheral type accounted for 95 and 109 cases, respectively. Although the patient population of the peripheral type was older, with a lower pathologic stage, lower lymphatic vessel involvement, and lymph node metastasis, the Kaplan-Meier survival proportions did not differ significantly between these two groups. Based on the histologic growth pattern, the peripheral type was classified under three subgroups as follows: 1). the alveolar space-filling type, 2). the expanding type, and 3). the combined type. Among these three types, the alveolar space-filling type showed neither lymphatic vessel invasion nor lymph node metastasis and had the most favorable prognosis. The central and peripheral types of lung squamous cell carcinoma have different clinicopathologic characteristics and should be classified under respectively different categories.

Adult↗

PubMed2002

Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis.

BACKGROUND: Although postoperative morbidity and mortality rates in patients with lung cancer have decreased with advances in perioperative management, those patients with idiopathic pulmonary fibrosis (IPF) remain at a high risk of complication and death. The frequency of postoperative morbidity and mortality rates in patients with lung cancer who have IPF have seldom been reported, however. METHODS: A retrospective study of 711 patients with lung cancer who had undergone surgical resection was conducted. Medical records were retrospectively compared for factors that might affect postoperative morbidity and mortality in patients with and without IPF. RESULTS: Of the 711 patients with lung cancer, 53 (7.5%) had IPF. The patients with IPF had pulmonary morbidity and mortality more frequently than those without IPF (26% versus 9.1%, P < 0.01; 8% versus 0.8%; P < 0.01). The 5-year survival was 43% among patients with IPF and 64.2% among those without IPF. Overall survival in patients with IPF was significantly lower than in those without IPF (P < 0.01), but disease-free survival was similar in the groups. Thirty-five percent of the deaths (8 of 23) were not related to lung cancer in those patients with IPF, compared with 18% (35 of 199) of the deaths among those without IPF (P = 0.048). CONCLUSION: Patients with IPF showed markedly higher postoperative pulmonary morbidity and mortality than those without IPF. The survival rate of patients with IPF was lower because of pulmonary complications. Careful preoperative evaluation and perioperative management are required to achieve optimal surgical outcome in patients with lung cancer who have IPF.

Adenocarcinoma↗

PubMed2002

Encapsulated thymoma metastasizing to a pectoralis major muscle.

An extensive review of the literature suggests that ours is the first case of encapsulated thymoma metastasizing to a skeletal muscle. A 43-year-old man underwent thymothymectomy for encapsulated Masaoka's stage I thymoma. Four years after complete resection, the tumor metastasized to the left pectoralis major muscle. Although a few reports exist on encapsulated thymoma metastasizing to a distant site, the literature does not describe encapsulated thymoma metastasizing to a skeletal muscle insofar as we could find.

Adult↗

PubMed2002

Successful management of solitary malar metastasis from lung cancer.

A right malar mass developed in a 68-year-old man who had undergone right upper and middle bilobectomy for lung cancer 2 years previously. The mass was diagnosed to be a malar metastasis from lung cancer and was surgically resected because no other metastases were found. The patient is well without signs of recurrence 5 years after resection of the malar mass. This is the first report of a malar metastasis from lung cancer and of successful resection for malar metastasis.

Aged↗

PubMed2002

Immunohistochemical neuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung.

The clinical significance of neuroendocrine (NE) differentiation is unclear in large cell carcinoma (LCC) of the lung. Fifty-five surgically resected carcinomas of the lung with an original pathologic diagnosis of LCC were reviewed histologically with special attention to NE morphology. Antibodies against neural cell adhesion molecule (NCAM), chromogranin A (CGA) and synaptophysin (SY) were used to confirm the NE differentiation. Thirteen (24%) cases were classified as large cell neuroendocrine carcinoma, 9 (16%) as LCC with NE differentiation, and 33 (60%) as pure LCC. There was no significant difference in overall survival between the three groups. When the 55 carcinomas were divided into three groups depending on the number of NE marker expression, there was significantly better overall survival in the NE > or = 2 (P = 0.02). Multivariate analysis proved NE > or = 2 was an independent predictor of survival. The number of NE markers was more important in terms of survival than histological sub-classification.

Aged↗

PubMed2002

Treatment strategy for chylothorax after pulmonary resection and lymph node dissection for lung cancer.

OBJECTIVE: We reviewed our experience with iatrogenic chylothorax after pulmonary resections for lung cancer to evaluate our treatment strategy and to identify factors that predict the need for reoperation. METHODS: From July 1992 through February 2000, a total of 1110 patients underwent pulmonary resection (at least lobectomy) and systematic mediastinal lymph node dissection for lung cancer at our division. Twenty-seven patients (2.4%) had postoperative chylothorax develop. We initially treated 26 of these patients conservatively with complete oral intake cessation and total parenteral nutrition, and these patients constituted the subjects in this study. RESULTS: There were 21 men and 5 women with a median age of 62 years (range 44 to 80 years). The initial procedures were pneumonectomy in 2 cases, bilobectomy in 1 case, and lobectomy in 23 cases. Twenty-one patients (81%) had the condition cured with conservative treatment. These patients resumed a normal diet at a median of 8 days after chylothorax diagnosis (range 4-35 days). The remaining 5 patients (19%) underwent reoperation at a median of 14 days after diagnosis (range 5-35 days). Chest tube drainage of less than 500 mL during the first 24 hours after complete oral intake cessation and total parenteral nutrition predicted a cure with conservative treatment. CONCLUSION: Although most cases of chylothorax after pulmonary resection with systematic mediastinal lymph node dissection can be cured with a conservative strategy, early surgical intervention may be indicated if chest tube drainage is more than 500 mL during the first 24 hours after complete oral intake cessation and total parenteral nutrition.

Adult↗

PubMed1999

Treatment of peritoneal dissemination of gastric cancer with sequential methotrexate and 5-fluorouracil.

BACKGROUND: Pretreatment with methotrexate (MTX) followed by 5-fluorouracil (5-FU) (sequential MTX and 5-FU), exerts biochemical modulation in which the antitumor effect of 5-FU is enhanced by the preceding MTX. Since the early 1980s, the sequential MTX/5-FU regimen has been employed clinically for gastric cancer in Japan, with high response rates for undifferentiated type gastric carcinoma.METHODS: Peritoneal dissemination is more frequent in undifferentiated type carcinoma, we therefore employed sequential MTX and 5-FU for the treatment of 39 gastric cancer patients with peritoneal dissemination. We also investigated MTX levels in blood and ascitic fluid during the treatment.RESULTS: Partial response (PR) was achieved in 6 of 26 patients (23%) who had evaluable lesions. PR lesions included abdominal wall tumors, primary gastric foci, inguinal lymph node, and rectal stenosis. Ascites was eliminated in 50% of the patients, and pleural effusion disappeared in 2 patients.CONCLUSIONS: In our study, sequential MTX and 5-FU had low toxicity and was beneficial for advanced gastric cancer patients with peritoneal dissemination. Further investigation of this treatment as induction and postoperative adjuvant chemotherapy for Borrmann type 4 gastric cancer seems warranted.

Journal Article↗

PubMedDate not supplied

Progression of focal pure ground-glass opacity detected by low-dose helical computed tomography screening for lung cancer.

OBJECTIVE: To clarify the progression of focal pure ground-glass opacity (pGGO) detected by low-dose helical computed tomography (CT) screening for lung cancer. METHODS: A total of 15,938 low-dose helical CT examinations were performed in 2052 participants in the screening project, and 1566 of them were judged to have yielded abnormal findings requiring further examination. Patients with peripheral nodules exhibiting pGGO at the time of the first thin-section CT examination and confirmed histologically by thin-section CT after follow-up of more than 6 months were enrolled in the current study. Progression was classified based on the follow-up thin-section CT findings. RESULTS: The progression of the 8 cases was classified into 3 types: increasing size (n = 5: bronchioloalveolar carcinoma [BAC]), decreasing size and the appearance of a solid component (n = 2: BAC, n = 1; adenocarcinoma with mixed subtype [Ad], n = 1), and stable size and increasing density (n = 1: BAC). In addition, the decreasing size group was further divided into 2 subtypes: a rapid-decreasing type (Ad: n = 1) and a slow-decreasing type (BAC: n = 1). The mean period between the first thin-section CT and surgery was 18 months (range: 7-38 months). All but one of the follow-up cases of lung cancer were noninvasive whereas the remaining GGO with a solid component was minimally invasive. CONCLUSIONS: The pGGOs of lung cancer nodules do not only increase in size or density, but may also decrease rapidly or slowly with the appearance of solid components. Close follow-up until the appearance of a solid component may be a valid option for the management of pGGO.

Adenocarcinoma, Bronchiolo-Alveolar↗

PubMedDate not supplied

The pattern of lymphatic metastases in superficial squamous cell carcinoma of the esophagus.

BACKGROUND/AIMS: Lymphatic spread patterns in relation to the location of primary tumors of the superficial thoracic esophageal squamous cell carcinoma have not been well established. We therefore analyzed patterns of lymph node metastasis in these patients. METHODOLOGY: We reviewed medical records of 65 patients who underwent systematic three-field dissection for superficial squamous carcinoma of the thoracic esophagus from 1993 through 2000. RESULTS: Lymph node involvement was found in 0% (0/13) and 44% (23/52) of patients whose tumor invaded the muscularis mucosa and submucosal layer, respectively. The 5-year survival rate was 77% in the node-negative group and 59% in the node-positive group (P<0.05). None of the patients with upper thoracic esophageal cancer had metastasis to the mediastinal and abdominal nodes. Patients with lower thoracic esophageal tumors (Lt) had no metastasis to the cervical nodes. Patients with middle thoracic esophageal tumors (Mt) and Lt patients rarely had metastasis (2-5%) in the lower mediasinal nodes (Nos. 108-112). No patient with superficial thoracic esophageal cancer had metastasis to the subcarinal nodes in this study. CONCLUSIONS: In our series, no patient with intramucosal carcinoma had lymphatic metastases. Some patients with submucosal cancers metastasized beyond regional lymph nodes. However, this study suggests that subcarinal nodes might not need to be sampled or dissected in patients with superficial carcinoma of the thoracic esophagus. In Mt and Lt patients, metastases to the mediastinal nodes were infrequent (2-7%). Mediastinal nodes other than #107 can easily be sampled through cervical and abdominal incisions. Therefore, combined with lymph node sampling in cervical, mediasinal and abdominal stations through cervical and abdominal incisions, esophagectomy without thoracotomy might be acceptable in Mt and Lt patients with superficial squamous cell carcinoma of the esophagus.

Abdomen↗